JP2023518707A - タンパク質症に関連する徘徊を治療する方法 - Google Patents

タンパク質症に関連する徘徊を治療する方法 Download PDF

Info

Publication number
JP2023518707A
JP2023518707A JP2022554548A JP2022554548A JP2023518707A JP 2023518707 A JP2023518707 A JP 2023518707A JP 2022554548 A JP2022554548 A JP 2022554548A JP 2022554548 A JP2022554548 A JP 2022554548A JP 2023518707 A JP2023518707 A JP 2023518707A
Authority
JP
Japan
Prior art keywords
wandering
patient
dementia
disease
fasudil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022554548A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023518707A5 (cg-RX-API-DMAC10.html
Inventor
マカリスター，トーマス
ジェイコブソン，スヴェン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Woolsey Pharmaceuticals Inc
Original Assignee
Woolsey Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Woolsey Pharmaceuticals Inc filed Critical Woolsey Pharmaceuticals Inc
Publication of JP2023518707A publication Critical patent/JP2023518707A/ja
Publication of JP2023518707A5 publication Critical patent/JP2023518707A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022554548A 2020-03-25 2021-01-08 タンパク質症に関連する徘徊を治療する方法 Pending JP2023518707A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062994527P 2020-03-25 2020-03-25
US62/994,527 2020-03-25
US202063005913P 2020-04-06 2020-04-06
US63/005,913 2020-04-06
PCT/US2021/012587 WO2021194608A1 (en) 2020-03-25 2021-01-08 Methods of treating proteinopathy- associated wandering

Publications (2)

Publication Number Publication Date
JP2023518707A true JP2023518707A (ja) 2023-05-08
JP2023518707A5 JP2023518707A5 (cg-RX-API-DMAC10.html) 2024-01-16

Family

ID=77855102

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022554548A Pending JP2023518707A (ja) 2020-03-25 2021-01-08 タンパク質症に関連する徘徊を治療する方法

Country Status (7)

Country Link
US (2) US11642352B2 (cg-RX-API-DMAC10.html)
EP (1) EP4125879A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023518707A (cg-RX-API-DMAC10.html)
CN (1) CN115916187A (cg-RX-API-DMAC10.html)
CA (1) CA3170073A1 (cg-RX-API-DMAC10.html)
MX (1) MX2022011518A (cg-RX-API-DMAC10.html)
WO (1) WO2021194608A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021142183A1 (en) * 2020-01-09 2021-07-15 Woolsey Pharmaceuticals, Inc Methods of treating cortical dementia associated wandering
US12329761B2 (en) 2020-04-23 2025-06-17 Woolsey Pharmaceuticals, Inc. Methods of using rho kinase inhibitors to treat alzheimer's disease
EP4181925A4 (en) * 2020-07-14 2024-07-31 Woolsey Pharmaceuticals, Inc. METHODS OF TREATMENT OF PROTEINOPATHIES
CA3231484A1 (en) 2021-10-01 2023-04-06 Qinwen Mao Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy
CA3236338A1 (en) * 2021-11-12 2023-05-19 Woolsey Pharmaceuticals, Inc. Method of treating amyotrophic lateral sclerosis and dosing regimen for same
WO2023097151A1 (en) 2021-11-29 2023-06-01 Woolsey Pharmaceuticals, Inc. Methods of treating agitation and other dementia-associated behavioral symptoms
MX2024009983A (es) * 2022-02-17 2024-08-26 Woolsey Pharmaceuticals Inc Formulaciones orales de fasudil que enmascaran el sabor.
MX2024010030A (es) * 2022-02-17 2024-09-24 Woolsey Pharmaceuticals Inc Formulaciones orales de fasudil con resina de intercambio ionico.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120010196A1 (en) * 2010-04-02 2012-01-12 Qin Quingyu Methods of treating neurodegenerative disorders and diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3464012B2 (ja) 1993-04-05 2003-11-05 旭化成株式会社 精神症候治療剤
WO2000009133A1 (fr) * 1998-08-10 2000-02-24 Asahi Kasei Kogyo Kabushiki Kaisha Preparations orales, a liberation prolongee, a base de chlorhydrate de fasudil
WO2005117896A1 (de) 2004-06-03 2005-12-15 Schering Aktiengesellschaft Formulierungen, die fasudil, eine matrix und einem mantel enthalten
US20090318485A1 (en) * 2006-07-20 2009-12-24 Kalypsys, Inc. Novel inhibitors of rho kinase
EP2061314A4 (en) 2006-08-10 2010-08-04 Translational Genomics Res Inst CONNECTIONS TO IMPROVE LEARNING AND MEMORY
US20080044390A1 (en) 2006-08-11 2008-02-21 Xiaowei Jin Methods and compositions for the treatment of neurodegenerative disorders
US20110237600A1 (en) 2008-05-12 2011-09-29 Amnestix, Inc. Compounds for improving learning and memory
CN101612157A (zh) 2008-06-26 2009-12-30 天津红日药业股份有限公司 法舒地尔诱导成年脑内源性神经干细胞再生的用途
EP2825175B1 (en) 2012-03-12 2017-07-26 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Rho kinase inhibitors for use in treating amyotrophic lateral sclerosis
WO2017195224A1 (en) 2016-05-09 2017-11-16 Istituto Superiore Di Sanita' Rho gtpase activating bacterial toxins for use in the treatment of disorders of the central nervous system by mucosal administration
WO2021142183A1 (en) * 2020-01-09 2021-07-15 Woolsey Pharmaceuticals, Inc Methods of treating cortical dementia associated wandering
US12329761B2 (en) * 2020-04-23 2025-06-17 Woolsey Pharmaceuticals, Inc. Methods of using rho kinase inhibitors to treat alzheimer's disease
EP4181925A4 (en) * 2020-07-14 2024-07-31 Woolsey Pharmaceuticals, Inc. METHODS OF TREATMENT OF PROTEINOPATHIES

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120010196A1 (en) * 2010-04-02 2012-01-12 Qin Quingyu Methods of treating neurodegenerative disorders and diseases

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Fasudil hydrochloride ameliorates memory deficits in rat model of streptozotocin-induced Alzheimer's", BEHAVIOURAL BRAIN RESEARCH, vol. 351, JPN6025000162, 2018, pages 4 - 16, ISSN: 0005636683 *
"随一血管性痴呆患者の俳徊症状に対する塩酸fasudilの効果", 神経治療, vol. 13, no. 1, JPN6025000160, 1996, pages 43 - 50, ISSN: 0005636682 *
ALZHEIMER'S AND DEMENTIA, vol. Vol.11, O2-12-04, JPN6025028070, 20 July 2015 (2015-07-20), pages 203, ISSN: 0005908271 *
老年期認知症研究会誌, vol. 19, no. 5, JPN6025028071, 2012, ISSN: 0005908272 *

Also Published As

Publication number Publication date
CN115916187A (zh) 2023-04-04
CA3170073A1 (en) 2021-09-30
US11642352B2 (en) 2023-05-09
MX2022011518A (es) 2022-10-07
US20210299140A1 (en) 2021-09-30
US20230226073A1 (en) 2023-07-20
EP4125879A4 (en) 2024-04-03
EP4125879A1 (en) 2023-02-08
WO2021194608A1 (en) 2021-09-30

Similar Documents

Publication Publication Date Title
US11642352B2 (en) Methods of treating wandering in Lewy dody dementia
JP7766935B2 (ja) 皮質性認知症に関連する徘徊を治療する方法
US11771704B1 (en) Methods of using rho kinase inhibitors to treat alzheimer's disease
JP2023530120A (ja) 血管性認知症を治療するためのＲｈｏキナーゼ阻害剤の使用方法
US11311553B1 (en) Methods of treating 4-repeat tauopathies
US20230263806A1 (en) Methods of treating proteinopathies
US20230405017A1 (en) Methods of using rho kinase inhibitors to treat frontotemporal dementia
CN118251226A (zh) 治疗肌萎缩性侧索硬化症的方法以及其给药方案
WO2022046160A1 (en) Methods of treating age-related cognitive decline

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250411

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251003

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260120

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260714